NewGenIvf Group Ltd

NewGenIvf Group Ltd announced an independent Big Four valuation of approximately $19 million for its planned UAE-based cell sorting and cytometry leasing business. This valuation highlights the significant growth potential in the high-infertility GCC market, projected to reach $444 million by 2030. The company also appointed industry veteran Nadeem Malik as Senior Strategic Advisor to spearhead the UAE/GCC expansion, leveraging his expertise in IVF and cell sorting operations.

NewGenIvf Group Limited announced that its Board of Directors approved a 1-for-3 reverse stock split for all issued and unissued shares, including Class A and Class B ordinary shares and preferred shares. The reverse stock split will be effective at 12:01 a.m. (ET) on July 6, 2026, with trading on a split-adjusted basis commencing the same day on the Nasdaq Capital Market under a new CUSIP number. This action will reduce the number of outstanding Class A Ordinary Shares from approximately 10.26 million to 3.42 million, with fractional shares being rounded up to a full share.

NewGenIvf Group Ltd announced the issuance of 3,666,667 new shares, bringing its total outstanding shares to 10,073,535. This action, linked to its strategic acquisition of a 10% equity interest in K25.ai, helped the company reach a market capitalization of US$7,631,710 as of June 18, 2026. The company also made a subsequent US$10 million investment in K25.ai, reinforcing its strategic pivot towards AI and digital platforms and positioning it to meet Nasdaq's minimum market value requirements.

NewGenIvf Group Limited announced an additional strategic investment in PredicXion Group Limited (K25.ai), acquiring an extra 4% equity for US$4 million. This increases NewGenIvf's total ownership in K25.ai to 10%, based on an implied valuation of US$100 million. The investment completes K25.ai's US$10 million Pre-A round, and the company is now raising its Series A to support product launch and regional expansion. NewGenIvf also holds exclusive Asia-Pacific agency rights with K25.ai, deepening its strategic participation.

NewGenIVF Group Limited announced a further $4 million strategic investment in K25.ai, completing K25.ai's $10 million Pre-A round at a $100 million valuation. This investment is expected to increase NewGen's aggregate ownership in K25.ai to 10%. With the Pre-A round closed, K25.ai has commenced its Series A fundraising to accelerate product launch and regional expansion, supported by NewGen's expanded stake and exclusive Asia-Pacific agency rights.

NewGenIvf Group Ltd announced it has entered into a Repurchase and Forbearance Agreement with a significant investor, JAK Opportunities VI LLC. Under the agreement, NewGenIvf will repurchase all outstanding convertible notes and warrants previously issued to the investor, while the investor will forbear from converting notes or exercising warrants. This move is expected to eliminate potential equity dilution, strengthen the company's capital structure, and provide greater clarity for shareholders. The aggregate consideration is payable through a scheduled installment plan extending until late 2027, with the company having prepayment options.

NewGenIVF Group Limited announced a Repurchase and Forbearance Agreement with a significant investor to repurchase all outstanding convertible notes and warrants. This move aims to eliminate potential equity dilution, strengthen the company's capital structure, and provide greater clarity for existing and prospective shareholders. Management believes this will allow the company's equity value to more accurately reflect its underlying net asset position and long-term value potential. The aggregate consideration is payable through a scheduled installment plan extending through late 2027, with prepayment options available without penalty.

NewGenIvf Group Limited announced the appointment of four new independent directors to its Board of Directors. Ms. Lee Sze Mun's appointment was effective June 1, 2026. Mr. Lau Tsz Hin Vincent, Mr. Lam Chun Tung Patrick, and Mr. Cheung Kong Yiu joined the board effective June 8, 2026. These appointments are expected to enhance the company's corporate governance.

NewGenIvf Group Ltd exercised its top-up option to acquire an additional 4% equity in K25.ai, increasing its total holding to 6%. This US$4 million investment comprises US$2 million in cash/digital assets and 1.5 million newly issued Class A ordinary shares. Concurrently, NewGenIvf is adopting a Digital Asset Treasury strategy and plans to invite K25.ai's CEO and co-founders to its Board of Directors. The company's 6% stake in K25.ai is now valued at approximately US$6 million, and it retains an option to acquire a further 4%.

NewGenIvf Group Ltd announced it has exercised its top-up option to acquire an additional 4% equity interest in AI-native livestreaming prediction market platform K25.ai, increasing its total holding to 6%. This US$4 million investment, split between cash and shares, brings NewGen's stake in K25.ai to an approximate value of US$6 million. The company is also formally adopting a Digital Asset Treasury strategy to strengthen its reserve base and diversify strategic assets, with K25.ai's CEO Andy Cheung expected to join NewGen's Board of Directors to lead this initiative.